In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels

Neuropeptides

Volumn 45, Issue 4, 2011, Pages 301-307

  Purtell, Louise ^a   Sze, Lisa ^b   Loughnan, Georgina ^c   Smith, Ellie ^d   Herzog, Herbert ^a   Sainsbury, Amanda ^a,e   Steinbeck, Katharine ^c,f   Campbell, Lesley V ^a,g   Viardot, Alexander ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

Author keywords

Ghrelin; GLP 1; Obesity; Prader Willi syndrome; PYY

Indexed keywords

GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PEPTIDE YY;

ABDOMINAL FAT; ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; ENDOCRINE DISEASE; FEMALE; HUMAN; HUNGER; HYPERPHAGIA; INSULIN RESISTANCE; MALE; OBESITY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; SATIETY; SIGNAL TRANSDUCTION;

ADULT; BLOOD GLUCOSE; BODY COMPOSITION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HUNGER; HYPERPHAGIA; INSULIN; MALE; OBESITY; PEPTIDE YY; POSTPRANDIAL PERIOD; PRADER-WILLI SYNDROME; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 79960839413     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2011.06.001     Document Type: Article

References (43)

1. Adrian TE T.E.F.G., Bacarese-Hamilton A.J., Fuessl H.S., Polak J.M., Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985, 89:1070-1077.
2. Baggio L.L., Drucker D.J. Glucagon-like peptide-1 and glucagon-like peptide-2. Best Pract. Res. Clin. Endocrinol. Metab. 2004, 18:531-554.
3. Bizzarri C., Rigamonti A.E., Luce A., Cappa M., Cella S.G., Berini J., Sartorio A., Muller E.E., Salvatoni A. Children with Prader-Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children. Eur. J. Endocrinol. 2010, 162:499-505.
4. Brambilla P., Bosio L., Manzoni P., Pietrobelli A., Beccaria L., Chiumello G. Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am. J. Clin. Nutr. 1997, 65:1369-1374.
5. Brambilla P., Crino A., Bedogni G., Bosio L., Cappa M., Corrias A., Delvecchio M., Di Candia S., Gargantini L., Grechi E., Iughetti L., Mussa A., Ragusa L., Sacco M., Salvatoni A., Chiumello G., Grugni G. Metabolic syndrome in children with Prader-Willi syndrome: the effect of obesity. Nutr Metab Cardiovasc Dis 2010.
6. Butler M.G. Prader-Willi syndrome: current understanding of cause and diagnosis. Am. J. Med. Genet. 1990, 35:319-332.
7. Butler M.G., Bittel D.C., Talebizadeh Z. Plasma peptide YY and ghrelin levels in infants and children with Prader-Willi syndrome. J. Pediatr. Endocrinol. Metab. 2004, 17:1177-1184.
8. Carey D.G., Jenkins A.B., Campbell L.V., Freund J., Chisholm D.J. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996, 45:633-638.
9. Cassidy S. Prader-Willi syndrome. J. Med. Genet. 1997, 34:917-923.
10. Chelikani P.K., Haver A.C., Reidelberger R.D. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R39-46.
11. Cummings D.E. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol. behav. 2006, 89:71-84.
12. Degen L., Oesch S., Casanova M., Graf S., Ketterer S., Drewe J., Beglinger C. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005, 129:1430-1436.
13. DelParigi A., Tschop M., Heiman M.L., Salbe A.D., Vozarova B., Sell S.M., Bunt J.C., Tataranni P.A. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 2002, 87:5461-5464.
14. Drucker D. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002, 122:531-544.
15. Dykens E.M., Maxwell M.A., Pantino E., Kossler R., Roof E. Assessment of hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring) 2007, 15:1816-1826.
16. Gimenez-Palop O., Gimenez-Perez G., Mauricio D., Gonzalez-Clemente J.M., Potau N., Berlanga E., Trallero R., Laferrere B., Caixas A. A lesser postprandial suppression of plasma ghrelin in Prader-Willi syndrome is associated with low fasting and a blunted postprandial PYY response. Clin. Endocrinol. (Oxf) 2007, 66:198-204.
17. Goldstone A.P. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol. Metab. 2004, 15:12-20.
18. Goldstone A.P., Thomas E.L., Brynes A.E., Bell J.D., Frost G., Saeed N., Hajnal J.V., Howard J.K., Holland A., Bloom S.R. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J. Clin. Endocrinol. Metab. 2001, 86:4330-4338.
19. Goldstone A.P., Thomas E.L., Brynes A.E., Castroman G., Edwards R., Ghatei M.A., Frost G., Holland A.J., Grossman A.B., Korbonits M., Bloom S.R., Bell J.D. Elevated fasting plasma ghrelin in prader-willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J. Clin. Endocrinol. Metab. 2004, 89:1718-1726.
20. Goldstone A.P., Patterson M., Kalingag N., Ghatei M.A., Brynes A.E., Bloom S.R., Grossman A.B., Korbonits M. Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J. Clin. Endocrinol. Metab. 2005, 90:2681-2690.
21. Haqq A.M., Farooqi I.S., O'Rahilly S., Stadler D.D., Rosenfeld R.G., Pratt K.L., LaFranchi S.H., Purnell J.Q. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 2003, 88:174-178.
22. Haqq A.M., Muehlbauer M.J., Newgard C.B., Grambow S., Freemark M. The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. J. Clin. Endocrinol. Metab. 2010.
23. Hill A.J., Blundell J.E. Nutrients and behaviour: research strategies for the investigation of taste characteristics, food preferences, hunger sensations and eating patterns in man. J. Psychiatric Res. 1982, 17:203-212.
24. Karra E., Batterham R.L. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol. Cell. Endocrinol. 2010, 316:120-128.
25. Kennedy L., Bittel D.C., Kibiryeva N., Kalra S.P., Torto R., Butler M.G. Circulating adiponectin levels, body composition and obesity-related variables in Prader-Willi syndrome: comparison with obese subjects. Int. J. Obes. (Lond) 2006, 30:382-387.
26. Matsuzawa Y. The role of fat topology in the risk of disease. Int. J. Obes. 2008, 32:S83-S92.
27. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
28. McLaughlin T., Abbasi F., Lamendola C., Frayo R.S., Cummings D.E. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J. Clin. Endocrinol. Metab. 2004, 89:1630-1635.
29. Paik K.H., Choe Y.H., Park W.H., Oh Y.J., Kim A.H., Chu S.H., Kim S.W., Kwon E.K., Han S.J., Shon W.Y., Jin D.K. Suppression of acylated ghrelin during oral glucose tolerance test is correlated with whole-body insulin sensitivity in children with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 2006, 91:1876-1881.
30. Paik K.H., Jin D.K., Lee K.H., Armstrong L., Lee J.E., Oh Y.J., Kim S., Kwon E.K., Choe Y.H. Peptide YY, cholecystokinin, insulin and ghrelin response to meal did not change, but mean serum levels of insulin is reduced in children with Prader-Willi syndrome. J. Korean Med. Sci. 2007, 22:436-441.
31. Paik K.H., Lee M.K., Jin D.K., Kang H.W., Lee K.H., Kim A.H., Kim C., Lee J.E., Oh Y.J., Kim S., Han S.J., Kwon E.K., Choe Y.H. Marked suppression of ghrelin concentration by insulin in Prader-willi syndrome. J. Korean Med. Sci. 2007, 22:177-182.
32. Park Y.W., Heymsfield S.B., Gallagher D. Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass?. Int. J. Obes. Relat. Metab. Disord. 2002, 26:978-983.
33. Purnell J.Q., Weigle D.S., Breen P., Cummings D.E. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J. Clin. Endocrinol. Metab. 2003, 88:5747-5752.
34. Shapira N.A., Lessig M.C., Lewis M.H., Goodman W.K., Driscoll D.J. Effects of topiramate in adults with Prader-Willi syndrome. Am. J. Ment. Retard. 2004, 109:301-309.
35. Sode-Carlsen R., Farholt S., Rabben K.F., Bollerslev J., Schreiner T., Jurik A.G., Christiansen J.S., Hoybye C. Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome. Growth Horm. IGF Res. 2010, 20:179-184.
36. Stewart K.J., DeRegis J.R., Turner K.L., Bacher A.C., Sung J., Hees P.S., Shapiro E.P., Tayback M., Ouyang P. Usefulness of anthropometrics and dual-energy X-ray absorptiometry for estimating abdominal obesity measured by magnetic resonance imaging in older men and women. J. cardiopulm. rehabil. 2003, 23:109-114.
37. Talebizadeh Z., Butler M.G. Insulin resistance and obesity-related factors in Prader-Willi syndrome: comparison with obese subjects. Clin. Genet. 2005, 67:230-239.
38. Tauber M., Conte Auriol F., Moulin P., Molinas C., Delagnes V., Salles J.P. Hyperghrelinemia is a common feature of Prader-Willi syndrome and pituitary stalk interruption: a pathophysiological hypothesis. Horm. Res. 2004, 62:49-54.
39. Theodoro M.F., Talebizadeh Z., Butler M.G. Body composition and fatness patterns in Prader-Willi syndrome: comparison with simple obesity. Obesity (Silver Spring) 2006, 14:1685-1690.
40. Vincent R.P., le Roux C.W. The satiety hormone peptide YY as a regulator of appetite. J. Clin. Pathol. 2008, 61:548-552.
41. Wren A.M., Small C.J., Abbott C.R., Dhillo W.S., Seal L.J., Cohen M.A., Batterham R.L., Taheri S., Stanley S.A., Ghatei M.A., Bloom S.R. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001, 50:2540-2547.
42. Yang H. Central and peripheral regulation of gastric acid secretion by peptide YY. Peptides 2002, 23:349-358.
43. Zipf W.B., O'Dorisio T.M., Berntson G.G. Short-term infusion of pancreatic polypeptide: effect on children with Prader-Willi syndrome. Am. J. Clin. Nutr. 1990, 51:162-166.